Journey Medical (DERM) Gross Profit (2020 - 2026)

Journey Medical (DERM) has reported Gross Profit for 7 consecutive years, with $12.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 22.81% year-over-year to $12.4 million; the trailing twelve-month figure through Jun 2026 stood at $44.6 million (up 18.95% YoY), and the FY2025 full-year result was $40.9 million, up 16.11% from the prior year.
• Gross Profit grew to $12.4 million in Q2 2026 per DERM's latest filing, from $9.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $28.1 million in Q3 2023 and bottomed at $5.8 million in Q1 2023.
• Historically, Gross Profit has averaged $11.0 million across 5 years, with a median of $9.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Gross Profit surged 216.02% in 2023, then plunged 63.86% in 2024.
• Over 5 years, Gross Profit stood at $8.2 million in 2022, then jumped by 57.72% to $13.0 million in 2023, then slumped by 31.28% to $8.9 million in 2024, then increased by 19.0% to $10.6 million in 2025, then rose by 16.24% to $12.4 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $12.4 million, $9.7 million, and $10.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.